Table 2 Characteristics of 264 CERP patients genotyped to identify genetic factors associated with individual predisposition to nausea and vomiting.

From: Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients

Characteristic

CERP series

Sex, n (%)

  Male

138 (52)

  Female

126 (48)

  Age, years, median (range)

67.8 (21.2–90.1)

Cancer, n (%)

  Lung

73 (28)

  Gastrointestinal tract§

42 (16)

  Breast

34 (13)

  Gynecological tumors

23 (8.7)

  Head and neck

21 (8.0)

  Pancreas

21 (8.0)

  Urological

19 (7.2)

  Prostate

12 (4.5)

  Other*

19 (7.2)

  Concurrent chemotherapy, n (%)

156 (59)

Opioid, n (%)

  Morphinea

68 (26)

  Oxycodonea

61 (23)

  Fentanylb

63 (24)

  Buprenorphineb

72 (27)

  NVS, mean (SD)

10.2 (19.4)

  1. NVS, nausea-vomiting score.
  2. aOral; btransdermal administration.
  3. §Colon/rectum (n = 34), stomach/esophagus/duodenum (n = 8).
  4. *Myeloma (n = 9), sarcoma (n = 2), unknown (n = 2), not specified (n = 6).
Back to article page